Furthermore, in hepatocellular carcinoma, CCR4+ Tregs were observed and therapies targeting CCL22 (primary ligand of CCR4), using an antagonist or N-CCR4-Fc, blocked the accumulation of intratumoral CCR4+ Tregs, overcoming sorafenib resistance and sensitizing tumors to PD-1 (115). Here, CCR4 is linked to hepatocellular carcinoma.